Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
Summary
Third Opinion Trial Synopsis:
Scientists are testing a new treatment for Relapsed or Refractory Multiple Myeloma (MM) called UCARTCS1A. They want to see if it's safe and effective for patients by slowly giving the treatment in bigger doses until they find the maximum dose that patients can tolerate without side effects.
Scientists are testing a new treatment for Relapsed or Refractory Multiple Myeloma (MM) called UCARTCS1A. They want to see if it's safe and effective for patients by slowly giving the treatment in bigger doses until they find the maximum dose that patients can tolerate without side effects.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a Phase I, FIH, open-label, dose escalation study evaluating Safety and Efficacy of UCART targeting CS1 in patients with Relapsed or Refractory Multiple Myeloma (MM). The purpose of this study is to evaluate the safety and clinical activity of UCARTCS1A and to determine the Maximum Tolerated Dose (MTD).
This is a Phase I, FIH, open-label, dose escalation study evaluating Safety and Efficacy of UCART targeting CS1 in patients with Relapsed or Refractory Multiple Myeloma (MM). The purpose of this study is to evaluate the safety and clinical activity of UCARTCS1A and to determine the Maximum Tolerated Dose (MTD).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: